Biotechnology company Ascletis Pharma Inc (1672.HK) said on Tuesday that its subsidiary has announced the IND approval from National Medical Products Administration (NMPA) for its non-alcoholic steatohepatitis (NASH) drug candidate ASC40 ( TVB-2640).
According to the company, ASC40 (TVB-2640), which is an orally bioavailable, first-in-class inhibitor of fatty acid synthase (FASN), is currently in a global Phase 2 trial in NASH, of which the first patient was dosed in late April, 2019 in the USA.
Under the company's randomised, placebo-controlled global Phase 2 trial, the investigators are evaluating the impact of ASC40 (TVB-2640) in about 90 NASH patients in the United States and about 25-30 NASH patients in China. The investigators will evaluate ASC40 (TVB-2640)'s impact on levels of plasma triglycerides, liver enzymes, inflammatory and fibrotic biomarkers.
In the study, the participants will have at least 8% liver fat at baseline, as measured by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF) and evidence of stage F1 to F3 fibrosis.
The primary endpoint of the study is the impact of ASC40 (TVB-2640) on liver fat reduction, compared to baseline, following 12 weeks of daily, continuous dosing, concluded the company.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins